CONTEXT: Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists often cause volume retention and edema. A relationship between PPARgamma and renin may play a role in this process. OBJECTIVE: The aim was to examine the relationship between the PPARgamma gene and plasma renin activity (PRA) levels in human hypertension. DESIGN, PARTICIPANTS, AND MEASURES: A candidate gene association study was conducted with two distinct groups of human participants: Caucasian hypertensives (n = 395) and African-American hypertensives (n = 55). Single nucleotide polymorphisms of the PPAR(Upsilon) gene were analyzed. Phenotype studies were conducted after participants consumed a low-salt diet (10 mmol/d) for 7 d and included PRA and aldosterone measurements before and after a 60-min angiotensin II infusion (3 ng/kg x min). RESULTS: Participants homozygous for the minor allele of rs2959272 (CC) had significantly higher PRA levels at baseline (P = 0.016) than major allele carriers (AA, AC) in Caucasian-hypertensive participants. The association of the C allele carrier status with increased PRA levels was replicated in the group of African-American hypertensive participants (P = 0.027). The Fisher's combined P value for both observations was significant (P = 0.002). CONCLUSIONS: These results demonstrate the first known association between a PPARgamma single nucleotide polymorphism and alterations in PRA levels in humans with hypertension. This link between PPARgamma and renin raises the possibility of a genetically based mechanism for the increased volume retention and edema in some users of PPARgamma agonists.
CONTEXT: Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists often cause volume retention and edema. A relationship between PPARgamma and renin may play a role in this process. OBJECTIVE: The aim was to examine the relationship between the PPARgamma gene and plasma renin activity (PRA) levels in humanhypertension. DESIGN, PARTICIPANTS, AND MEASURES: A candidate gene association study was conducted with two distinct groups of humanparticipants: Caucasian hypertensives (n = 395) and African-American hypertensives (n = 55). Single nucleotide polymorphisms of the PPAR(Upsilon) gene were analyzed. Phenotype studies were conducted after participants consumed a low-salt diet (10 mmol/d) for 7 d and included PRA and aldosterone measurements before and after a 60-min angiotensin II infusion (3 ng/kg x min). RESULTS:Participants homozygous for the minor allele of rs2959272 (CC) had significantly higher PRA levels at baseline (P = 0.016) than major allele carriers (AA, AC) in Caucasian-hypertensiveparticipants. The association of the C allele carrier status with increased PRA levels was replicated in the group of African-American hypertensiveparticipants (P = 0.027). The Fisher's combined P value for both observations was significant (P = 0.002). CONCLUSIONS: These results demonstrate the first known association between a PPARgamma single nucleotide polymorphism and alterations in PRA levels in humans with hypertension. This link between PPARgamma and renin raises the possibility of a genetically based mechanism for the increased volume retention and edema in some users of PPARgamma agonists.
Authors: Richard W Nesto; David Bell; Robert O Bonow; Vivian Fonseca; Scott M Grundy; Edward S Horton; Martin Le Winter; Daniel Porte; Clay F Semenkovich; Sidney Smith; Lawrence H Young; Richard Kahn Journal: Circulation Date: 2003-12-09 Impact factor: 29.690
Authors: Olga Gumieniak; Todd S Perlstein; Jonathan S Williams; Paul N Hopkins; Nancy J Brown; Benjamin A Raby; Gordon H Williams Journal: Hypertension Date: 2007-01-15 Impact factor: 10.190
Authors: Sheng Zhong Duan; Christine Y Ivashchenko; Steven E Whitesall; Louis G D'Alecy; Damon C Duquaine; Frank C Brosius; Frank J Gonzalez; Charles Vinson; Melissa A Pierre; David S Milstone; Richard M Mortensen Journal: J Clin Invest Date: 2007-02-15 Impact factor: 14.808
Authors: Jian Song; Mark A Knepper; Xinqun Hu; Joseph G Verbalis; Carolyn A Ecelbarger Journal: J Pharmacol Exp Ther Date: 2003-10-30 Impact factor: 4.030
Authors: David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman Journal: Diabetes Care Date: 2008-10-22 Impact factor: 17.152
Authors: Patricia C Underwood; Bindu Chamarthi; Jonathan S Williams; Bei Sun; Anand Vaidya; Benjamin A Raby; Jessica Lasky-Su; Paul N Hopkins; Gail K Adler; Gordon H Williams Journal: Metabolism Date: 2011-11-08 Impact factor: 8.694
Authors: Luminita H Pojoga; Patricia C Underwood; Mark O Goodarzi; Jonathan S Williams; Gail K Adler; Xavier Jeunemaitre; Paul N Hopkins; Benjamin A Raby; Jessica Lasky-Su; Bei Sun; Jinrui Cui; Xiuqing Guo; Kent D Taylor; Yii-Der Ida Chen; Anny Xiang; Leslie J Raffel; Thomas A Buchanan; Jerome I Rotter; Gordon H Williams Journal: J Clin Endocrinol Metab Date: 2011-05-25 Impact factor: 5.958
Authors: Alexander W Krug; Eric Tille; Bei Sun; Luminita Pojoga; Jonathan Williams; Bindu Chamarthi; Andrew H Lichtman; Paul N Hopkins; Gail K Adler; Gordon H Williams Journal: Age (Dordr) Date: 2012-10-02
Authors: Andrea V Haas; Li En Yee; Yan E Yuan; Yin H Wong; Paul N Hopkins; Xavier Jeunemaitre; Jessica Lasky-Su; Jonathan S Williams; Gail K Adler; Gordon H Williams Journal: Hypertension Date: 2021-11-10 Impact factor: 10.190
Authors: Tina Gupta; Molly Connors; Jia Wei Tan; Worapaka Manosroi; Noha Ahmed; Pei Yee Ting; Amanda E Garza; Jose R Romero; Paul N Hopkins; Jonathan S Williams; Gordon H Williams Journal: Am J Hypertens Date: 2017-12-08 Impact factor: 2.689
Authors: A D Rao; B Sun; A Saxena; P N Hopkins; X Jeunemaitre; N J Brown; G K Adler; J S Williams Journal: J Hum Hypertens Date: 2012-05-31 Impact factor: 3.012